| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b51619c4c541c872f86910f69003b4bb |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-20 |
| filingDate |
2012-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_900bb928f1aa2cc07040ca5f6793b214
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5d839bd35a0ab65c55b9e84bf90bffe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39f7eb86072cb306b61277c8aaa95ce4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_509b2b7f132ea2736f67b43b3f8ce923
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f38085db7e64002c8858428f10ad917f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_864ed95c6366cd23f0e7e5e55b0d864a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27876f3c672b7dcc2e0ccc93bb3e2e90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b90192e3e070b88b8a583af9cfb96c0 |
| publicationDate |
2014-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-102911271-B |
| titleOfInvention |
Anti-CTNNB1 monoclonal antibody 12H7 and application thereof |
| abstract |
The invention discloses a hybridoma cell strain the conservation number of which is CGMCC No.6135, and a monoclonal antibody 12H7 produced from the hybridoma cell strain. The invention also relates to an application of the monoclonal antibody 12H7 in manufacturing an immunodetection tool for detecting beta-Catenin protein, an immunohistochemical kit containing the monoclonal antibody 12H7 and the application of the monoclonal antibody 12H7 in manufacturing a kit for detecting beta-Catenin-related tumors. The monoclonal antibody described by the invention can be specifically combined with beta-Catenin protein, and is free of cross reaction with other protein in cells, thus significantly improving the specificity and reliability of immunodetection of beta-Catenin protein. |
| priorityDate |
2012-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |